Next Generation Sequencing of giant cell tumor of bone for the elucidation of pathology and the discovery of novel therapeutic target

• Project/Area Number: 25462323
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: The University of Tokyo
• Principal Investigator: Tanaka Takeyuki 東京大学, 医学部附属病院, 助教 (00583121)
• Co-Investigator(Kenkyū-buntansha): KAWANO Hirotaka 帝京大学, 医学部, 教授 (20345218) ; KAWAGUCHI Hiroshi 東京大学, 医学部附属病院, 届出診療員 (40282660)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 骨・軟部腫瘍 / 骨巨細胞腫

Outline of Final Research Achievements

Giant cell tumors of bone (GCTB) is a locally aggressive neoplasm of bone, with a propensity for recurrence.RANK ligand secreted by the immature osteoblast-like stromal cells of these tumors induce the formation of osteoclast-like giant cells. RANKL is a therapeutic target of osteoporosis and bone metastasis, but the mechanism of the expression is unexplained. To elucidate the mechanism of RANKL expression, we performed this research with next generation sequencing. We will continue this research to discover new therapeutic target for GCTB.